These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32397906)

  • 21. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
    Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir.
    Martin R; Li J; Parvangada A; Perry J; Cihlar T; Mo H; Porter D; Svarovskaia E
    Antiviral Res; 2021 Apr; 188():105033. PubMed ID: 33549572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
    Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
    Moirangthem DS; Surbala L
    Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
    Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
    SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
    Ko M; Chang SY; Byun SY; Ianevski A; Choi I; Pham Hung d'Alexandry d'Orengiani AL; Ravlo E; Wang W; Bjørås M; Kainov DE; Shum D; Min JY; Windisch MP
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33918958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.
    Focosi D; Maggi F; McConnell S; Casadevall A
    Antiviral Res; 2022 Feb; 198():105247. PubMed ID: 35033572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
    Elfiky AA
    Life Sci; 2020 Jul; 253():117592. PubMed ID: 32222463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
    Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the molecular structure of Remdesivir for the treatment of Covid-19.
    Sheikholeslami SM; Jahanbani A; Shao Z
    Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance.
    Grimes SL; Choi YJ; Banerjee A; Small G; Anderson-Daniels J; Gribble J; Pruijssers AJ; Agostini ML; Abu-Shmais A; Lu X; Darst SA; Campbell E; Denison MR
    mBio; 2023 Aug; 14(4):e0106023. PubMed ID: 37338298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
    Kokic G; Hillen HS; Tegunov D; Dienemann C; Seitz F; Schmitzova J; Farnung L; Siewert A; Höbartner C; Cramer P
    Nat Commun; 2021 Jan; 12(1):279. PubMed ID: 33436624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations.
    Nguyen HL; Thai NQ; Truong DT; Li MS
    J Phys Chem B; 2020 Dec; 124(50):11337-11348. PubMed ID: 33264025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
    El-Sayed NS; Jureka AS; Edwards MR; Lohan S; Williams CG; Keiser PT; Davey RA; Totonchy J; Tiwari RK; Basler CF; Parang K
    Eur J Med Chem; 2021 Dec; 226():113862. PubMed ID: 34583312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19.
    Jiang Y; Yin W; Xu HE
    Biochem Biophys Res Commun; 2021 Jan; 538():47-53. PubMed ID: 32943188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment.
    Agoni C; Soliman MES
    Curr Pharm Biotechnol; 2021; 22(11):1520-1537. PubMed ID: 33109039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
    Taha HR; Keewan N; Slati F; Al-Sawalha NA
    Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
    Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
    Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.